BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN) today announced that data from previous Phase 1 and Phase 2a clinical studies for NG2-73, the Company’s lead compound for the treatment of insomnia, will be presented in three sessions at the SLEEP 2007 Annual Meeting of the Associated Professional Sleep Societies (APSS) in Minneapolis, Minnesota on June 11 and 13. Two Phase 2b clinical studies with NG2-73 in chronic insomnia patients are currently being conducted by the Company.
